Lilly Asia Ventures logo

Lilly Asia Ventures

Asia, Shanghai, China, Shanghai

Description

Lilly Asian Ventures is an investment firm that invests in promising life science companies.

Investor Profile

Lilly Asia Ventures has made 119 investments, with 11 in the past 12 months and 18% as lead.

Stage Focus

  • Series A (31%)
  • Series B (29%)
  • Series C (20%)
  • Series Unknown (5%)
  • Series E (4%)
  • Series D (3%)
  • Post Ipo Equity (2%)
  • Private Equity (2%)
  • Seed (2%)
  • Convertible Note (1%)

Country Focus

  • China (50%)
  • United States (46%)
  • Hong Kong (2%)
  • Israel (1%)
  • South Korea (1%)
  • United Kingdom (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Therapeutics
  • Biopharma
  • Medical Device
  • Life Science
  • Oncology
  • Manufacturing
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Lilly Asia Ventures frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 35
CA
North America, Massachusetts, United States, Boston
Co-Investments: 13
Temasek Holdings
Asia, Central Region, Singapore, Singapore
Co-Investments: 10
Matrix Partners China
Asia, Beijing, China, Beijing
Co-Investments: 11
Octagon Capital Advisors
North America, New York, United States, New York
Co-Investments: 13
HongShan
Asia, Beijing, China, Beijing
Co-Investments: 12
Qiming Venture Partners
Asia, Shanghai, China, Shanghai
Co-Investments: 14
Vivo Capital
North America, California, United States, Palo Alto
Co-Investments: 19
Eight Roads Ventures
Europe, England, United Kingdom, London
Co-Investments: 9
ARCH Venture Partners
North America, Illinois, United States, Chicago
Co-Investments: 18

Which angels does Lilly Asia Ventures often collaborate with?

Zohar Zisapel
Asia, Tel Aviv, Israel, Tel Aviv
Shared Deals: 1
SI
North America, New York, United States, New York
Shared Deals: 1

What are some of recent deals done by Lilly Asia Ventures?

Rona Therapeutics

Shanghai, Shanghai, China

Rona Therapeutics is a RNA therapeutics platform enabling discovery, development of modular and programmable RNA medicines.

BiotechnologyHealth CareMedicalTherapeutics
Series BMar 14, 2025
Amount Raised: $25,000,000
Pulnovo Medical

Wuxi, Anhui, China

Pulnovo Medical is a medical device company, specializing in the treatment of pulmonary artery hypertension.

Health CareMedicalMedical Device
Series CMar 3, 2025
Amount Raised: $100,000,000
Stairway Medical

Pudong, Shandong, China

Stairway Medical is a developer of implantable brain-computer interface technology.

Health CareMedicalMedical Device
Series BFeb 10, 2025
Amount Raised: $47,908,454
Fine Vision

Nanjing, Jiangsu, China

Fine Vision is a provider of solutions for ophthalmic illnesses.

EyewearHealth CareMedical
Series AJan 16, 2025
Timberlyne Therapeutics

San Diego, California, United States

Timberlyne Therapeutics is a biopharmaceutical company that develops therapies for autoimmune diseases.

BiopharmaBiotechnologyHealth Care
Series AJan 9, 2025
Amount Raised: $180,000,000
Verdiva Bio

London, England, United Kingdom

Verdiva Bio creates cutting-edge treatments that improve results for patients with obesity and cardiometabolic diseases.

BiotechnologyHealth CareMedical
Series AJan 9, 2025
Amount Raised: $411,000,000
Syneron

Guangzhou, Guangdong, China

Syneron is a company that using artificial intelligence and biotechnology to address two significant global challenges.

Artificial Intelligence (AI)Biotechnology
Series ANov 19, 2024
Avenzo Therapeutics

San Diego, California, United States

Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.

BiotechnologyHealth CareMedicalOncologyTherapeutics
Series ANov 18, 2024
Chimagen Biosciences

Chengdu, Sichuan, China

Chimagen Biosciences is a company that is creating a novel class of multi-functional monoclonal antibodies for cancer therapy.

BiotechnologyHealth CareMedical
Series BOct 31, 2024
XellSmart

Minhang, Shanghai, China

Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments.

BiopharmaBiotechnologyPharmaceutical
Series BOct 21, 2024
Amount Raised: $14,046,917